Trial Condition(s):
Deep Vein Thrombosis
Venous thromboembolism (VTE) treatment study in Japanese deep vein thrombosis (DVT) patients
Bayer Identifier:
14568
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of two different dosages of rivaroxaban in the treatment of deep vein thrombosis (DVT) and the prevention of the occurrence and the recurrence of DVT or pulmonary embolism (PE) in Japanese patients with acute symptomatic DVT without symptomatic PE.
Inclusion Criteria
- Men and women >/= 20 years of age in patients with confirmed acute symptomatic proximal deep vein thrombosis (DVT) without symptomatic pulmonary embolism (PE)
Exclusion Criteria
- Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT - More than 48 hours pre-randomization treatment with therapeutic dosages of anti-coagulant treatment or more than a single dose of warfarin from the onset of the current episode of DVT to randomization - Calculated creatinine clearance (CLCR) < 30 mL/min - Subjects with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk - Active bleeding or high risk for bleeding contraindicating treatment with unfractioned Heparin (UFH) or warfarin - Systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | Status | |
|---|---|---|
Locations Investigative Site Sapporo, Japan, 006-8555 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Itabashi-ku, Japan, 173-8610 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Meguro-ku, Japan, 152-8902 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Yokohama, Japan, 245-8575 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Toyoake, Japan, 470-1192 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Osakasayama, Japan, 589-8511 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Otake, Japan, 739-0696 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Maebashi, Japan, 371-8511 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Bunkyo-ku, Japan, 113-8655 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Niigata, Japan, 951-8520 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kanazawa, Japan, 920-8650 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kahoku-gun, Japan, 920-0293 | Status Completed | Contact Us: E-mail: [email protected]re.com Phone: Not Available |
Locations Investigative Site Tsu, Japan, 514-8507 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Osaka, Japan, 530-8480 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Kumamoto, Japan, 862-8505 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Aomori, Japan, 030-8553 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Suita, Japan, 565-8565 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Shinagawa, Japan, 141-8625 | Status Terminated | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sakura, Japan, 285-8741 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Chuoku, Japan, 104-8560 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Shinjuku-ku, Japan, 162-8655 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Shizuoka, Japan, 424-8636 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Osaka, Japan, 537-8511 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Tokushima, Japan, 770-8503 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Wakayama, Japan, 640-8158 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Sasebo, Japan, 857-8511 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Fukuoka, Japan, 810-0001 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Takarazuka, Japan, 665-0827 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Locations Investigative Site Okayama, Japan, 701-1192 | Status Completed | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Randomized, open-label (double blind among rivaroxaban groups in the initial 3 weeks), parallel-group, active-controlled study of rivaroxaban in patients with acute symptomatic deep vein thrombosis without symptomatic pulmonary embolism
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Randomized
Blinding:
Double Blind
Assignment:
Parallel Assignment
Trial Arms:
4
Primary Outcome
- Number of participants with newly onset of symptomatic venous thromboembolism (VTE)Timeframe: Up to 12 months
- Number of clinically relevant bleedingsTimeframe: Up to 2 days after last dose
Secondary Outcome
- Number of participants with improvement in thrombotic burdenTimeframe: At week 3
- Number of participants with deterioration in thrombotic burdenTimeframe: Up to 12 months
- Number of participants with the composite of newly onset of symptomatic VTE or asymptomatic deterioration of thrombusTimeframe: Up to 12 months
Additional Information
Copyright © Bayer
Powered by
